News

ATCC Expands Board of Directors With Three Appointments

ATCC, the world’s premier biological materials management and standards organization, announced that Dr. Melissa Rewolinski, Steve Curts and Heather Kiessling have joined its board of directors. ATCC’s board helps advise the senior leadership team on a variety of business, strategy and science-related issues. Board members work closely with management to identify new opportunities to deepen ATCC’s impact within the scientific community and grow its business.

“Our leadership and impact on the scientific research community during the pandemic served as a catalyst for growth, and we are confident that the experience and perspective that Melissa, Steve and Heather offer will complement the experience of our Board and help enable us to continue to grow our business and advance our company’s leadership at the forefront of science, said Raymond H. Cypess, D.V.M., Ph.D., chairman and CEO of ATCC. “We are fortunate to have a variety of talented and dedicated board members to help lead ATCC during this important time in our history.”

Dr. Rewolinski has served as a scientific leader, research and development executive and board member in the pharmaceutical industry for over 25 years. She earned her doctoral degree in organic chemistry from Rice University and started her career as a senior research scientist for Pfizer, studying isomers, metabolites and impurities within chemical research and development. Rewolinski rose to serve as a research and development and operations senior executive responsible for strategic development and growth, inventing multiple patents and managing multiple development functions including product development, clinical operations and regulatory affairs. Rewolinski will serve on the BioNexus Foundation, and Science and Technology Committees of ATCC’s board.

Mr. Curts joins the ATCC board as a finance expert on managing global portfolios. As the managing director of portfolio operations for Centares, Curts leads operational initiatives, portfolio oversight and leverages capabilities across Centares’ portfolio. He previously served as chief strategy officer for American Express Global Business Travel, responsible for strategy, acquisitions and partnerships for joint ventures and private equity investors. With a passion for service, he resided as vice president of Dell Services, transforming their service delivery model to realize $3.5 billion in revenue. Curts will serve as a key member of the ATCC Cell Systems (ACS) and Finance and Audit Committees.

Ms. Kiessling is a certified public accountant who brings more than 25 years of business intelligence in finance, operational improvement, research and development, and other cross-functional areas. Her impressive achievements include supporting a range of companies at various stages, including start-up, early-stage and fast-growing organizations in both the private and public sectors. She has demonstrated acumen in overseeing corporate operations and financial reporting, ensuring transparency to all stakeholders. Kiessling will serve as chair of the Finance and Audit Committee of the ATCC board and contribute to the ACS Committee.

Recent News

04/08/2026

Likarda and The Tiny Cargo Company Announce Strategic Partnership to Advance Next-Generation Delivery of Biologics, Peptides and Small Molecules

Likarda, Inc., a leader in hydrogel-based drug delivery technologies, today announced a strategic partnership with Tiny Cargo, an innovator in extracellular vesicle (EV) delivery systems. The collaboration will focus on advancing the delivery of biologics and small molecules by integrating Likarda’s Core-Shell Spherification® (CSS®) platform with Tiny Cargo’s vesicle-based technologies. The partnership is designed to

04/08/2026

ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the closing of an oversubscribed $40 million financing. This brings the total capital raised to date to more than $150 million.

04/02/2026

ATCC Receives New CDC Award to Help Fast-track Diagnostic Tests for Future Disease Outbreaks

TCC has been selected by the Centers for Disease Control and Prevention (CDC) Office of Readiness and Response (ORR) for a new five-year contract to support rapid test development during public health emergencies. The award, valued at up to $148 million (IDIQ contract 75D301-25-R-73207), will help ensure that diagnostic tools can be quickly created, validated,